Search Browse Earnings

Xilio Therapeutics, Inc. — SlamSEC

Xilio Therapeutics, Inc.

Nasdaq:XLO

Pharmaceutical Preparations·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$6.3M

FY 2024

Adj. EBITDA

-$77.2M

-1217.4% margin

FY 2024

Net Income

-$76.4M

-1204.4% margin

FY 2024

EPS (Diluted)

-$2.78

FY 2024

Stock Price

$0.53

-1.4%

2026-03-06

52W Range

$0.50 – $1.18

P/E Ratio

-0.2x

Market Cap

$27.8M

Cash

$44.7M

FY 2024

Total Debt

$6.5M

FY 2023

Net Cash

$38.2M

FY 2023

Enterprise Value

-$10.4M

Debt / EBITDA

0.5x

FY 2024

EV / EBITDA

0.1x

Employees

—